WallStSmart

Newmont Goldcorp Corp (NEM)vsSanofi ADR (SNY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Sanofi ADR generates 106% more annual revenue ($46.72B vs $22.67B). NEM leads profitability with a 31.2% profit margin vs 16.7%. NEM appears more attractively valued with a PEG of 2.78. NEM earns a higher WallStSmart Score of 65/100 (B-).

NEM

Strong Buy

65

out of 100

Grade: B-

Growth: 6.7Profit: 9.0Value: 4.7Quality: 8.0
Piotroski: 6/9Altman Z: 2.04

SNY

Hold

49

out of 100

Grade: D+

Growth: 4.7Profit: 6.0Value: 4.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NEMSignificantly Overvalued (-184.1%)

Margin of Safety

-184.1%

Fair Value

$43.86

Current Price

$101.52

$57.66 premium

UndervaluedFair: $43.86Overvalued
SNYSignificantly Overvalued (-89.7%)

Margin of Safety

-89.7%

Fair Value

$24.79

Current Price

$46.03

$21.24 premium

UndervaluedFair: $24.79Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NEM6 strengths · Avg: 9.3/10
Profit MarginProfitability
31.2%10/10

Keeps 31 of every $100 in revenue as profit

Operating MarginProfitability
58.1%10/10

Strong operational efficiency at 58.1%

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Market CapQuality
$108.06B9/10

Large-cap with strong market position

Return on EquityProfitability
22.3%9/10

Every $100 of equity generates 22 in profit

P/E RatioValuation
15.3x8/10

Attractively priced relative to earnings

SNY3 strengths · Avg: 9.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

Market CapQuality
$109.03B9/10

Large-cap with strong market position

Free Cash FlowQuality
$1.59B8/10

Generating 1.6B in free cash flow

Areas to Watch

NEM2 concerns · Avg: 2.0/10
PEG RatioValuation
2.782/10

Expensive relative to growth rate

EPS GrowthGrowth
-4.6%2/10

Earnings declined 4.6%

SNY3 concerns · Avg: 3.0/10
EPS GrowthGrowth
2.4%4/10

2.4% earnings growth

Return on EquityProfitability
6.7%3/10

ROE of 6.7% — below average capital efficiency

PEG RatioValuation
4.322/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : NEM

The strongest argument for NEM centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 31.2% and operating margin at 58.1%. Revenue growth of 20.6% demonstrates continued momentum.

Bull Case : SNY

The strongest argument for SNY centers on Price/Book, Market Cap, Free Cash Flow. Profitability is solid with margins at 16.7% and operating margin at 14.3%.

Bear Case : NEM

The primary concerns for NEM are PEG Ratio, EPS Growth.

Bear Case : SNY

The primary concerns for SNY are EPS Growth, Return on Equity, PEG Ratio.

Key Dynamics to Monitor

NEM profiles as a growth stock while SNY is a mature play — different risk/reward profiles.

NEM carries more volatility with a beta of 0.39 — expect wider price swings.

NEM is growing revenue faster at 20.6% — sustainability is the question.

SNY generates stronger free cash flow (1.6B), providing more financial flexibility.

Bottom Line

NEM scores higher overall (65/100 vs 49/100), backed by strong 31.2% margins and 20.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Newmont Goldcorp Corp

BASIC MATERIALS · GOLD · USA

Newmont Corporation, based in Greenwood Village, Colorado, United States, is one of the largest gold mining companies in the world.

Visit Website →

Sanofi ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.

Want to dig deeper into these stocks?